Navigation Links
Isis Reports Financial Results and Highlights for Fiscal year 2007
Date:3/13/2008

by Isis and Isis' partners, the Company anticipates many clinical events for 2008; some are highlighted below:
* Isis' cardiovascular franchise will continue to provide clinical

evidence to support the activity and safety profiles of

second-generation antisense drugs. Isis completed two key goals

early, including the licensing of mipomersen, the lead drug in this

franchise, to Genzyme and the initiation of Phase 3 studies of

mipomersen in patients with Familial Hypercholesterolemia.

* Over the upcoming months, Isis expects to effect a seamless

transition of mipomersen development to Genzyme.

* Isis and Genzyme expect to report new safety data for

mipomersen.

* Isis expects to initiate Phase 1 clinical studies of ISIS

353512 that targets CRP for the treatment of coronary artery

disease.

* Isis and BMS expect to advance into development a drug

targeting PCSK9 for the treatment of cardiovascular disease.

* Isis' metabolic franchise, which consists of four novel and

complementary drugs to treat type 2 diabetes, will continue to grow,

with clinical data expected from the most advanced of the four drugs,

ISIS 113715, and Isis will continue to explore the therapeutic

opportunities for antisense drugs to treat obesity.

* Isis expects to report Phase 2 study data in Type 2 diabetics

treated with ISIS 113715 and sulfonylureas.

* Isis expects to complete the Phase 1 study of ISIS 325568, an

antisense drug licensed to OMI that targets GCGR to treat

diabetes. Isis expects OMI will choose to initiate Phase 2

studies of ISIS 325568 in patients with type 2 diabetes.

* Isis' partners developing antisense drugs
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... A group of nine authors involved with ... Inspire Award at DIA’s upcoming Annual Meeting. DIA’s Global ... their leadership, level of excellence, and commitment to service ... of the Author(s) of the Year Award, which acknowledges ... made a significant impact in advancing medical product development, ...
(Date:6/3/2015)... 03, 2015 Z-Medica®, LLC, a leading ... June has been designated as National Safety Month by ... AZ. Police Department for its commitment to public safety. ... their Individual First Aid Kits (IFAK) over 100 times ... shootings, stabbings or traffic accidents. Each kit is equipped ...
(Date:6/3/2015)... June 03, 2015 Researchers at the ... for mesothelioma and say the tried-and-true marker mesothelin is ... an article on the research. Click here to ... National Center for Asbestos Related Diseases say, even though ... it is still preferable to fibulin-3 for identifying mesothelioma. ...
(Date:6/3/2015)... According to an article published on May14th by ... pills which actually contained the potent addictive drug fentanyl. ... even sported the “A/215” imprint common on real oxycodone ... oxycodone to be exceptionally critical of their prescriptions—especially those ... on the street. Fentanyl is an opiate-based narcotic and ...
(Date:6/3/2015)... Atlanta, GA (PRWEB) June 03, 2015 ... A in Duluth, GA will celebrate its grand opening ... 2015. , The first prosthetic center of its kind ... and their family unmatched care and outcomes through use ... Keith Watson, CPO & CEO of Fourroux Prosthetics, states, ...
Breaking Medicine News(10 mins):Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2
... , , WASHINGTON, July 22 There ... (H.R. 3200) that concern citizens who care greatly about the freedom to ... bill: , , * Eliminates Existing Private ... "Acceptable" to the Federal Government, But Is Just Fine With You ...
... , , , ... consecutive year, Regence won four bronze (second-place) Telly Awards for originally created ... Web site for Regence members. , , ... of non-news and advertising video production; Regence,s videos were selected from more ...
... , SAN DIEGO, July 22 ... it intends to offer, subject to market and other conditions, 9,000,000 ... connection with this offering, Orexigen expects to grant to the underwriter ... of common stock to cover overallotments, if any. All of the ...
... , LANCASTER, Pa., July 22 The Board of Directors for Herley ... management leadership. , , , ... Lieberman named Chairman of The Board , Richard Poirier ... Walker (Ret.) to continue as Vice Chairman of the Board , ...
... Finding may lead to new treatments, researcher says , WEDNESDAY, ... thrombomodulin, which is involved in blood clotting and preventing cell ... new Canadian study suggests. , The finding might lead to ... about 300 children affected by it in the United States, ...
... such program in world started in Australia , WEDNESDAY, ... readying its first human trials of an experimental vaccine ... announced Wednesday. , Two possible vaccines will be tested ... of the National Institute of Allergy and Infectious Diseases ...
Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 3Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 4Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 5Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 2Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 2Health News:U.S. Swine Flu Vaccine Trials Set to Begin 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 4Health News:U.S. Swine Flu Vaccine Trials Set to Begin 5Health News:U.S. Swine Flu Vaccine Trials Set to Begin 6Health News:U.S. Swine Flu Vaccine Trials Set to Begin 7Health News:U.S. Swine Flu Vaccine Trials Set to Begin 8Health News:U.S. Swine Flu Vaccine Trials Set to Begin 9Health News:U.S. Swine Flu Vaccine Trials Set to Begin 10Health News:U.S. Swine Flu Vaccine Trials Set to Begin 11Health News:U.S. Swine Flu Vaccine Trials Set to Begin 12Health News:U.S. Swine Flu Vaccine Trials Set to Begin 13
(Date:6/3/2015)... 3, 2015 AVT, Inc. (OTC Markets: AVTC) ... systems, announced today that their customer, Pharmabox, has introduced ... self-service kiosk carries over 140 top selling brand name ... Walgreen,s or Rite Aid-type store. As ... Miami -based Pharmabox worked with AVT ...
(Date:6/3/2015)... DIEGO , June 3, 2015  Halozyme ... a global collaboration and license agreement with AbbVie ... combining proprietary AbbVie compounds with Halozyme,s ENHANZE ™ ... of the agreement, Halozyme will receive an initial ... approximately $130 million for each of up to ...
(Date:6/3/2015)... 3, 2015 According to ... Peripheral Vascular Devices Market (Embolic Protection, Chronic Total ... Grafts, IVC Filters, Stents, Balloons and Accessories) - ... Cardiology and Peripheral Vascular Devices Market is expected ... a CAGR of 7.4% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmabox Introduces New Concept with a Boldly Designed Automated Retailing System 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
... Inc. (NYSE: VRX ) (TSX: VRX) today announced ... Internet webcast along with a slide presentation on Thursday, February ... discuss results for the 2010 fourth quarter and full year. ... is (877) 295-5743, confirmation code 41335702.  International callers should dial ...
... PARK, Calif., Feb. 15, 2011 ForteBio®, Inc., a ... of biotherapeutic and pharmaceutical products, today announced the launch ... new Dip and Read Protein L Biosensor for use ... widen the scope and utility of the company,s flagship ...
Cached Medicine Technology:Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor 2
... product solutions were developed to assist in ... To maximize use of existing capital equipment, ... the productivity of their employees, organizations are ... their valuable assets and ensure those assets ...
... Mobile Location-ID™ offers a for asset tracking electronically. ... to all the assets that will be tracked. ... equipped with a reader, antenna, and a portable ... small as 10 inches x 6 inches. One ...
Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
... provides hospitals with a suite ... all their supplies, drugs, assets, ... remove all manual compliance from ... accurately. iRIS, or Intelligent Radio-Frequency ...
Medicine Products: